Vericel director sells 7,000 shares after option exercise
Vericel Corp director Kevin F. McLaughlin reported option exercises and related stock sales in Vericel common stock.
Rhea-AI Filing Summary
Vericel Corp director Kevin F. McLaughlin reported option exercises and related stock sales in Vericel common stock. On May 13, 2026, he exercised stock options to acquire a total of 7,000 shares of common stock, including 3,500 shares at an exercise price of $13.05 per share and 3,500 shares at $2.63 per share. On the same date, he sold 7,000 shares in open‑market transactions at prices of $32.82 and $32.83 per share. After these transactions, McLaughlin directly held 18,300 shares of Vericel common stock. The filing notes that the sales were automatic transactions executed under a Rule 10b5-1 trading plan adopted on May 12, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,000 shares ($175K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
MCLAUGHLIN KEVIN F
Role
Director
Sold
7,000 shs ($230K)
Approx. gross sale proceeds
$230K
Approx. exercise cost
$55K
Approx. pre-tax spread
$175K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,500 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 3,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,500 | $2.63 | $9K |
| Sale | Common Stock | 3,500 | $32.83 | $115K |
| Exercise | Common Stock | 3,500 | $13.05 | $46K |
| Sale | Common Stock | 3,500 | $32.82 | $115K |
Holdings After Transaction:
Stock Option (Right to Buy) — 14,000 contracts (Direct);
Common Stock — 18,300 shares (Direct)
Footnotes (3)
- F1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025.
- F2. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.
- F3. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.
Key Figures
Shares sold: 7,000 shares
Sale prices: $32.82 and $32.83 per share
Options exercised: 7,000 shares
+3 more
6 metrics
Shares sold
7,000 shares
Open-market sales on May 13, 2026
Sale prices
$32.82 and $32.83 per share
Common stock sales on May 13, 2026
Options exercised
7,000 shares
Total shares from option exercises on May 13, 2026
Exercise prices
$13.05 and $2.63 per share
Stock option exercise prices for common stock
Shares held after
18,300 shares
Direct ownership after transactions
10b5-1 plan adoption date
May 12, 2025
Date trading plan governing sales was adopted
Key Terms
Rule 10b5-1 trading plan, automatic sale, Stock Option (Right to Buy), Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
automatic sale financial
"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transactions did Vericel (VCEL) director Kevin F. McLaughlin report?
Kevin F. McLaughlin reported exercising options for 7,000 Vericel shares and selling 7,000 shares. The sales were open‑market transactions executed under a pre‑arranged Rule 10b5-1 trading plan.
What stock options did Kevin F. McLaughlin exercise in Vericel (VCEL)?
He exercised options covering 7,000 shares of Vericel common stock: 3,500 shares at a $13.05 exercise price and 3,500 shares at a $2.63 exercise price, both originally granted in 2017 and 2018.
Were Kevin F. McLaughlin’s Vericel (VCEL) stock sales pre-planned?
Yes. The filing states the sales were automatic transactions under a Rule 10b5-1 trading plan adopted on May 12, 2025, indicating they were pre‑scheduled rather than discretionary market‑timing decisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
